Mengke Pharmaceutical is an antibacterial drug developer. Its main product is MRX-I, an oxazolidinone antibacterial drug for the treatment of methicillin-resistant Staphylococcus aureus infection. This product can reduce adverse blood reactions caused by antibacterial drugs. At the same time, it can reduce the bone marrow suppression toxicity of oxazolidinone antibiotics, and provide a new solution for related treatment. Mengke Pharmaceutical’s public offering on the Shanghai Stock Exchange today.
This article is reprinted from: https://www.itjuzi.com/pre-ipo?comname=%E7%9B%9F%E7%A7%91%E8%8D%AF%E4%B8%9A
This site is for inclusion only, and the copyright belongs to the original author.